By Peter A. McCullough, MD, MPH
Throughout the disastrous COVID-19 injection campaign, desperate patients have often asked me which is the safest vaccine? It is odd that two years into mass vaccination there is no declared “best in class” vaccine. Entities that mandate the vaccine don’t care which vaccine is administered, only that a student, athlete, employee, or soldier has been marked by one of them any time in the past—often without any regard to its six month efficacy window. Many thought initially that the Johnson and Johnson (Janssen) product would be safer since it was just one shot of an adenoviral vector vaccine (not mRNA). Unfortunately before COVID-19 it was known that the vector itself was thrombogenic. So combined with the genetic code for the Spike protein which is known to damage blood vessels and cause blood clots, the Janssen vaccine was expected to cause thromboembolism in patients from the very date of its release. Woo et al from the FDA in a report has described thousands (N=3790, 11% fatal) of patients with blood clots and their description of what happens in the human body is nothing short of “blood curdling.” Clots going from the ankle to the groin, shooting to both lungs, and killing the victim is a description out of a science fiction horror movie yet in this report produced by our own government gives no apologies nor raises a sense of alarm for the public.
I wonder if a similar analysis for the mRNA vaccines would find the same degree of clot burden. In my clinical experience the mRNA and adenoviral vaccines are equally dangerous. As in the Woo report, the events with Janssen appear occur in a shorter time window (median 12 days) in proximity to the injection whereas the long lasting mRNA can drive catastrophic events months later. One thing is clear, for COVID-19 it is “buyer beware” however the weary public is not doing the buying, rather they are having the ill-fated products effectively forced into their bodies with terrible consequences.
If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.
Woo EJ, Mba-Jonas A, Thomas A, Baer B, Day B, Kim Y, Gomez-Lorenzo M, Nair N. Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. 2022 Nov;31(11):1174-1181. doi: 10.1002/pds.5523. Epub 2022 Sep 5. PMID: 36065046; PMCID: PMC9538147.